Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise

Research output: Contribution to journalArticlepeer-review


Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments.

Original languageEnglish (US)
Pages (from-to)3173-3175
Number of pages3
JournalClinical Cancer Research
Issue number15
StatePublished - Aug 1 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise'. Together they form a unique fingerprint.

Cite this